Literature DB >> 3771746

Increased incidence of fungemia caused by Candida krusei.

W G Merz, J E Karp, D Schron, R Saral.   

Abstract

Candida krusei colonized 12.4% of 868 patients undergoing episodes of therapy-induced granulocytopenia over a 9-year period. The gastrointestinal tract was most frequently colonized, followed by the respiratory tract and urinary tract. Ten patients developed systemic infections with C. krusei; all 10 had two or more positive blood cultures. Nine of the 10 patients were colonized with C. krusei, and 6 were receiving systemic antifungal agents at the time of development of the infection. Seven patients died within 1 month of C. krusei sepsis; systemic candidiasis was seen in the autopsies of the four patients on whom autopsies were performed. Therefore, C. krusei should be recognized as an emerging pathogen in select patient populations.

Entities:  

Mesh:

Year:  1986        PMID: 3771746      PMCID: PMC268975          DOI: 10.1128/jcm.24.4.581-584.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Fungemia with compromised host resistance. A study of 70 cases.

Authors:  R C Young; J E Bennett; G W Geelhoed; A S Levine
Journal:  Ann Intern Med       Date:  1974-05       Impact factor: 25.391

2.  The correlation of maximal drug dose, tumor recruitment, and sequence timing with therapeutic advantage: schedule-dependent toxicity of cytosine arabinoside.

Authors:  P J Burke; W P Vaughan; J E Karp; P L Saylor
Journal:  Med Pediatr Oncol       Date:  1982

3.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

Authors:  R Horn; B Wong; T E Kiehn; D Armstrong
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

4.  The value of fungal surveillance cultures as predictors of systemic fungal infections.

Authors:  G R Sandford; W G Merz; J R Wingard; P Charache; R Saral
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

5.  Systemic candidiasis in cancer patients.

Authors:  A W Maksymiuk; S Thongprasert; R Hopfer; M Luna; V Fainstein; G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

6.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

7.  The prevalence of yeasts in clinical specimens from cancer patients.

Authors:  T E Kiehn; F F Edwards; D Armstrong
Journal:  Am J Clin Pathol       Date:  1980-04       Impact factor: 2.493

8.  Candida tropicalis: a major pathogen in immunocompromised patients.

Authors:  J R Wingard; W G Merz; R Saral
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

9.  Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients.

Authors:  R E Slavin; M A Dias; R Saral
Journal:  Cancer       Date:  1978-10       Impact factor: 6.860

10.  Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.

Authors:  P J Burke; J E Karp; H G Braine; W P Vaughan
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

View more
  33 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Failure of fluconazole therapy in Candida krusei fungemia.

Authors:  B L Røder; C Sonnenschein; S H Hartzen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Evaluation of the Microring YT system for identifying clinical yeast isolates.

Authors:  E J Ridgway; K D Allen
Journal:  J Clin Pathol       Date:  1991-09       Impact factor: 3.411

5.  Rapid identification of Candida species by DNA fingerprinting with PCR.

Authors:  M Thanos; G Schonian; W Meyer; C Schweynoch; Y Graser; T G Mitchell; W Presber; H J Tietz
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

6.  Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors:  M A Fisher; S H Shen; J Haddad; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Nosocomial Candida glabrata colonization: an epidemiologic study.

Authors:  J A Vazquez; L M Dembry; V Sanchez; M A Vazquez; J D Sobel; C Dmuchowski; M J Zervos
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

8.  Systemic Candida infection in University hospital 1997-1999: the distribution of Candida biotypes and antifungal susceptibility patterns.

Authors:  K P Ng; T L Saw; S L Na; T S Soo-Hoo
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

9.  Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice.

Authors:  N C Karyotakis; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 10.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.